{"id":121187,"date":"2023-04-12T21:30:14","date_gmt":"2023-04-12T14:30:14","guid":{"rendered":"http:\/\/10.223.74.30:38922\/openarchive\/?post_type=tnc_col_2494_item&#038;p=121187"},"modified":"2023-06-07T12:01:31","modified_gmt":"2023-06-07T05:01:31","slug":"safety-and-immunogenicity-of-intradermal-administration-of-fractional-dose-coronavac-r-chadox1-ncov-19-and-bnt162b2-as-primary-series-vaccination","status":"publish","type":"tnc_col_2494_item","link":"https:\/\/www.nstda.or.th\/openarchive\/nstda-research-publications\/safety-and-immunogenicity-of-intradermal-administration-of-fractional-dose-coronavac-r-chadox1-ncov-19-and-bnt162b2-as-primary-series-vaccination\/","title":{"rendered":"Safety and immunogenicity of intradermal administration of fractional dose CoronaVac (R), ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination"},"content":{"rendered":"","protected":false},"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","format":"standard","class_list":["post-121187","tnc_col_2494_item","type-tnc_col_2494_item","status-publish","format-standard","hentry","tnc_tax_2222-adverse-effect","tnc_tax_2222-covid-vaccine","tnc_tax_2222-fractional-dose-vaccination","tnc_tax_2222-heterologous-regimen","tnc_tax_2222-intradermal-vaccine","tnc_tax_2222-vaccine-immunogenicity","tnc_tax_2222-vaccine-safety"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Safety and immunogenicity of intradermal administration of fractional dose CoronaVac (R), ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination - NSTDA Open Repository<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nstda.or.th\/openarchive\/nstda-research-publications\/safety-and-immunogenicity-of-intradermal-administration-of-fractional-dose-coronavac-r-chadox1-ncov-19-and-bnt162b2-as-primary-series-vaccination\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Safety and immunogenicity of intradermal administration of fractional dose CoronaVac (R), ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination - NSTDA Open Repository\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nstda.or.th\/openarchive\/nstda-research-publications\/safety-and-immunogenicity-of-intradermal-administration-of-fractional-dose-coronavac-r-chadox1-ncov-19-and-bnt162b2-as-primary-series-vaccination\/\" \/>\n<meta property=\"og:site_name\" content=\"NSTDA Open Repository\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-07T05:01:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.nstda.or.th\/openarchive\/wp-content\/uploads\/2019\/02\/cropped-cropped-aw-nstda-color-1-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2000\" \/>\n\t<meta property=\"og:image:height\" content=\"625\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nstda.or.th\\\/openarchive\\\/nstda-research-publications\\\/safety-and-immunogenicity-of-intradermal-administration-of-fractional-dose-coronavac-r-chadox1-ncov-19-and-bnt162b2-as-primary-series-vaccination\\\/\",\"url\":\"https:\\\/\\\/www.nstda.or.th\\\/openarchive\\\/nstda-research-publications\\\/safety-and-immunogenicity-of-intradermal-administration-of-fractional-dose-coronavac-r-chadox1-ncov-19-and-bnt162b2-as-primary-series-vaccination\\\/\",\"name\":\"Safety and immunogenicity of intradermal administration of fractional dose CoronaVac (R), ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination - NSTDA Open Repository\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nstda.or.th\\\/openarchive\\\/#website\"},\"datePublished\":\"2023-04-12T14:30:14+00:00\",\"dateModified\":\"2023-06-07T05:01:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.nstda.or.th\\\/openarchive\\\/nstda-research-publications\\\/safety-and-immunogenicity-of-intradermal-administration-of-fractional-dose-coronavac-r-chadox1-ncov-19-and-bnt162b2-as-primary-series-vaccination\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nstda.or.th\\\/openarchive\\\/nstda-research-publications\\\/safety-and-immunogenicity-of-intradermal-administration-of-fractional-dose-coronavac-r-chadox1-ncov-19-and-bnt162b2-as-primary-series-vaccination\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.nstda.or.th\\\/openarchive\\\/nstda-research-publications\\\/safety-and-immunogenicity-of-intradermal-administration-of-fractional-dose-coronavac-r-chadox1-ncov-19-and-bnt162b2-as-primary-series-vaccination\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.nstda.or.th\\\/openarchive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NSTDA's Research Publications\",\"item\":\"https:\\\/\\\/www.nstda.or.th\\\/openarchive\\\/nstda-research-publications\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Safety and immunogenicity of intradermal administration of fractional dose CoronaVac (R), ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nstda.or.th\\\/openarchive\\\/#website\",\"url\":\"https:\\\/\\\/www.nstda.or.th\\\/openarchive\\\/\",\"name\":\"NSTDA Open Repository\",\"description\":\"NSTDA Open Repository is a digital open-access repository for NSTDA&#039;s research publications, including manuscripts, journal articles conference papers, reviews, and more. The publications are made available in the Repository on terms of Creative Commons License. You may read, download, share, and re-use for your research as long as you abide by the license under which an item has been released.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nstda.or.th\\\/openarchive\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nstda.or.th\\\/openarchive\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nstda.or.th\\\/openarchive\\\/#organization\",\"name\":\"National Science and Technology Development Agency\",\"url\":\"https:\\\/\\\/www.nstda.or.th\\\/openarchive\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.nstda.or.th\\\/openarchive\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.nstda.or.th\\\/openarchive\\\/wp-content\\\/uploads\\\/2019\\\/02\\\/cropped-cropped-aw-nstda-color-1-1.png\",\"contentUrl\":\"http:\\\/\\\/www.nstda.or.th\\\/openarchive\\\/wp-content\\\/uploads\\\/2019\\\/02\\\/cropped-cropped-aw-nstda-color-1-1.png\",\"width\":2000,\"height\":625,\"caption\":\"National Science and Technology Development Agency\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nstda.or.th\\\/openarchive\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Safety and immunogenicity of intradermal administration of fractional dose CoronaVac (R), ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination - NSTDA Open Repository","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nstda.or.th\/openarchive\/nstda-research-publications\/safety-and-immunogenicity-of-intradermal-administration-of-fractional-dose-coronavac-r-chadox1-ncov-19-and-bnt162b2-as-primary-series-vaccination\/","og_locale":"en_US","og_type":"article","og_title":"Safety and immunogenicity of intradermal administration of fractional dose CoronaVac (R), ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination - NSTDA Open Repository","og_url":"https:\/\/www.nstda.or.th\/openarchive\/nstda-research-publications\/safety-and-immunogenicity-of-intradermal-administration-of-fractional-dose-coronavac-r-chadox1-ncov-19-and-bnt162b2-as-primary-series-vaccination\/","og_site_name":"NSTDA Open Repository","article_modified_time":"2023-06-07T05:01:31+00:00","og_image":[{"width":2000,"height":625,"url":"https:\/\/www.nstda.or.th\/openarchive\/wp-content\/uploads\/2019\/02\/cropped-cropped-aw-nstda-color-1-1.png","type":"image\/png"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.nstda.or.th\/openarchive\/nstda-research-publications\/safety-and-immunogenicity-of-intradermal-administration-of-fractional-dose-coronavac-r-chadox1-ncov-19-and-bnt162b2-as-primary-series-vaccination\/","url":"https:\/\/www.nstda.or.th\/openarchive\/nstda-research-publications\/safety-and-immunogenicity-of-intradermal-administration-of-fractional-dose-coronavac-r-chadox1-ncov-19-and-bnt162b2-as-primary-series-vaccination\/","name":"Safety and immunogenicity of intradermal administration of fractional dose CoronaVac (R), ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination - NSTDA Open Repository","isPartOf":{"@id":"https:\/\/www.nstda.or.th\/openarchive\/#website"},"datePublished":"2023-04-12T14:30:14+00:00","dateModified":"2023-06-07T05:01:31+00:00","breadcrumb":{"@id":"https:\/\/www.nstda.or.th\/openarchive\/nstda-research-publications\/safety-and-immunogenicity-of-intradermal-administration-of-fractional-dose-coronavac-r-chadox1-ncov-19-and-bnt162b2-as-primary-series-vaccination\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nstda.or.th\/openarchive\/nstda-research-publications\/safety-and-immunogenicity-of-intradermal-administration-of-fractional-dose-coronavac-r-chadox1-ncov-19-and-bnt162b2-as-primary-series-vaccination\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.nstda.or.th\/openarchive\/nstda-research-publications\/safety-and-immunogenicity-of-intradermal-administration-of-fractional-dose-coronavac-r-chadox1-ncov-19-and-bnt162b2-as-primary-series-vaccination\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.nstda.or.th\/openarchive\/"},{"@type":"ListItem","position":2,"name":"NSTDA's Research Publications","item":"https:\/\/www.nstda.or.th\/openarchive\/nstda-research-publications\/"},{"@type":"ListItem","position":3,"name":"Safety and immunogenicity of intradermal administration of fractional dose CoronaVac (R), ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination"}]},{"@type":"WebSite","@id":"https:\/\/www.nstda.or.th\/openarchive\/#website","url":"https:\/\/www.nstda.or.th\/openarchive\/","name":"NSTDA Open Repository","description":"NSTDA Open Repository is a digital open-access repository for NSTDA&#039;s research publications, including manuscripts, journal articles conference papers, reviews, and more. The publications are made available in the Repository on terms of Creative Commons License. You may read, download, share, and re-use for your research as long as you abide by the license under which an item has been released.","publisher":{"@id":"https:\/\/www.nstda.or.th\/openarchive\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nstda.or.th\/openarchive\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.nstda.or.th\/openarchive\/#organization","name":"National Science and Technology Development Agency","url":"https:\/\/www.nstda.or.th\/openarchive\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.nstda.or.th\/openarchive\/#\/schema\/logo\/image\/","url":"http:\/\/www.nstda.or.th\/openarchive\/wp-content\/uploads\/2019\/02\/cropped-cropped-aw-nstda-color-1-1.png","contentUrl":"http:\/\/www.nstda.or.th\/openarchive\/wp-content\/uploads\/2019\/02\/cropped-cropped-aw-nstda-color-1-1.png","width":2000,"height":625,"caption":"National Science and Technology Development Agency"},"image":{"@id":"https:\/\/www.nstda.or.th\/openarchive\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.nstda.or.th\/openarchive\/wp-json\/wp\/v2\/tnc_col_2494_item\/121187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nstda.or.th\/openarchive\/wp-json\/wp\/v2\/tnc_col_2494_item"}],"about":[{"href":"https:\/\/www.nstda.or.th\/openarchive\/wp-json\/wp\/v2\/types\/tnc_col_2494_item"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nstda.or.th\/openarchive\/wp-json\/wp\/v2\/comments?post=121187"}],"version-history":[{"count":1,"href":"https:\/\/www.nstda.or.th\/openarchive\/wp-json\/wp\/v2\/tnc_col_2494_item\/121187\/revisions"}],"predecessor-version":[{"id":140539,"href":"https:\/\/www.nstda.or.th\/openarchive\/wp-json\/wp\/v2\/tnc_col_2494_item\/121187\/revisions\/140539"}],"wp:attachment":[{"href":"https:\/\/www.nstda.or.th\/openarchive\/wp-json\/wp\/v2\/media?parent=121187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}